*Schedule subject to change. Schedules are posted in Eastern Standard Time (EST). Additional dates and speakers to be announced.
Josip Blonder, M.D., Senior Research Scientist, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick Inc., NCI-Frederick
John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
David Brown, Ph.D., Director, Research and Development, Asuragen, Inc.
George A. Calin, M.D., Ph.D., Associate Professor, Experimental Therapeutics & Cancer Genetics, The University of Texas, M.D. Anderson Cancer
Walter P. Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Dx
Mark R. Chance, Ph.D., Director, Center for Proteomics & Synchrotron Biosciences, Physiology & Biophysics, School of Medicine, Case Western Reserve University
Giora Z. Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research Laboratories
Martin Fleisher, Ph.D., Chair, Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center
Richard A. Frank, M.D., Ph.D., FFPM (RCP), Vice President, Global Medical Affairs and Clinical Strategy, GE Healthcare
Herbert A. Fritsche, Ph.D., Professor and Chief, Clinical Chemistry, Department of Laboratory Medicine, The University of Texas, M.D. Anderson Cancer Center
Federico Goodsaid, Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology/Office of Translational Sciences/ Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Samir M. Hanash, M.D., Ph.D., Program Head, Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center
J. Milburn Jessup, M.D., Chief, Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD/National Cancer Institute
Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research Laboratory, Department of Pathology,Stony Brook University Medical Center
Bing Kuang, Ph.D., Principal Scientist, Translational Research, PDM, PGRD, Pfizer, Inc.
Bruce H. Littman, M.D., President, Translational Medicine Associates LLC
Ruth E. March, Ph.D., Lead, Personalized Healthcare Team, AstraZeneca Pharmaceuticals
Christopher-Paul Milne, D.V.M., M.P.H., J.D., Associate Director, Tufts Center for the Study of Drug Development, Tufts University
Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
Shannon Payne, Ph.D., Senior Scientist, Epigenomics, Inc.
Emanuel F. Petricoin III, Ph.D., Professor, Life Sciences & Company Director, Applied Proteomics & Molecular Medicine, George Mason University
Reena Philip, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH/FDA
Paul W. Rhyne, Ph.D., Associate Director, Bioanalytical Sciences, Bristol Myers Squibb Co.
Frank Richardson, Ph.D., Senior Director, Safety Assessment & Molecular Markers, OSI Pharmaceuticals
Karin D. Rodland, Ph.D., Science Lead, NIH Programs, Biological Sciences, Pacific Northwest National Laboratory
Anderson Ryan, Ph.D., Principle Translational Scientist, Cancer BioScience, Global Discovery Science Lead and Translational Science Strategist for ZACTIMA (vandetanib) project, AstraZeneca
Jeffrey Shuster, Ph.D., Director, Diagnostics Development, Metabolon, Inc.
Georgina Speake, Ph.D., Translational Science Strategist, Cancer BioScience, Global Discovery Science Lead and Translational Science Strategist for IRESSA (gefitinib) project, AstraZeneca
David F. Stroncek, M.D., Chief, Cell Processing, National Institutes of Health Clinical Center
Anna Szafranska-Schwarzbach, Ph.D., CLIA Laboratory Supervisor, Pharmacogenomics Services, Asuragen, Inc.
Ruth A. VanBogelen, Ph.D., Director, Biomarkers & Proteomics, NextGen Sciences, Inc.